This enduring program, derived from the virtual live event, to focus on the rationale and evidence for and the future clinical incorporation of TROP2-targeted ADCs into the treatment plan for patients with advanced non small-cell lung cancer (NSCLC). As such, these “Highlights” cover the key points of the Virtual Live event in a more succinct format designed for online consumption. A link to the full Virtual Live recording for learners who wish to deepen their understanding of the content will be available. As a result of this educational curriculum, learners should be better able to: 1. Identify the rationale for using TROP2-directed ADCs in the treatment of patients with advanced NSCLC; 2. Review clinical evidence on emerging TROP2-directed ADCs in patients with advanced NSCLC; and 3. Describe clinical implications related to the use of TROP2-directed ADCs, as available, for patients with advanced NSCLC, based on the evidence
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/QJC
- Start Date: 2024-12-26 06:00:00
- End Date: 2024-12-26 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 45342.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 45342.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all